EGFR and breast cancer: CTD downregulates epidermal growth factor receptor (EGFR) through mir607, and blocks the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and extracellular regulated protein kinases (ERK)/mitogen-activated protein kinase (MAPK) signaling pathways to inhibit the proliferation of BT474 and MDAMB-468 breast cancer cells (Yang et al., 2023).